Attention: The information presented in this article is intended solely for educational and research purposes and is directed to laboratory professionals, researchers, and collaborators. This content does not constitute medical or clinical advice.

---

What Is CJC-1295?

CJC-1295 is a synthetic peptide that acts as a growth hormone (GH) secretagogue. It is used in medical and sports nutrition contexts to support muscle mass development, reduction of body fat, and improved recovery following physical exercise.

---

CJC-1295 Without DAC

Without DAC (Drug Affinity Complex):
This form of CJC-1295 is a version that does not contain the modification responsible for extending its half-life. As a result, it produces faster biological activity, but its duration in the body is shorter compared to the DAC-modified version.

The effects may appear more rapidly, but more frequent administrations are required due to the shorter half-life.

---

CJC-1295 With DAC

With DAC:
This version contains the Drug Affinity Complex, which allows for slower and more sustained release of the peptide within the body.

This modification significantly extends the peptide’s half-life, enabling users to experience growth hormone–related effects over a longer period without requiring daily administration. The gradual release also allows for a more convenient dosing profile.

---

Comparison

Duration of Action

CJC-1295 with DAC exhibits a significantly longer duration of activity, whereas the version without DAC produces more immediate but shorter-lasting effects.

Frequency of Administration

CJC-1295 without DAC requires more frequent administration, while the DAC-modified version can be administered less frequently due to its extended half-life.

Usage Objectives

The choice between these two forms depends on individual goals, such as training objectives and preferences related to dosing convenience.

---

Pulsatile vs. Sustained GH Secretion Patterns

The distinction between these secretion patterns extends beyond simple duration differences, representing qualitatively different experimental systems.

The limited functional stability of modified GRF 1-29 results in shorter receptor occupancy periods between exposures. This promotes receptor internalization, recycling, and resensitization, helping maintain physiological responsiveness.

Research shows that pulsatile GH exposure maximizes activation of STAT5b, a transcription factor responsible for regulating many GH-responsive genes, including IGF-1.

In contrast, continuous exposure reduces STAT5b activation to approximately 10–20% of maximal levels, despite higher total GH concentrations, suggesting altered signal transduction dynamics.

The DAC-free variant is particularly suitable for investigations requiring:

• physiological pulsatile secretion patterns
• studies involving intact feedback mechanisms
• examination of acute GH effects on target cells
• receptor sensitivity investigations
• experiments analyzing pulse frequency or amplitude

Conversely, DAC-modified variants are more suitable for studies examining sustained GH-axis activation and chronic metabolic adaptations over longer time periods.

Mechanisms of Action in Research Models

GHRH Receptor Binding and Activation

CJC-1295 without DAC exerts its biological activity through specific binding to growth hormone–releasing hormone receptors (GHRHR), which belong to the class B1 G protein–coupled receptor superfamily.

These receptors are primarily expressed in somatotroph cells of the anterior pituitary, although they have also been identified in brain regions, pancreatic tissue, and cardiac myocytes.

The receptor structure consists of seven transmembrane domains with an extensive extracellular N-terminal region responsible for recognizing peptide ligands.

The modified GRF 1-29 preserves the N-terminal residues essential for receptor recognition, explaining its binding affinity even after modifications in the central peptide sequence.

Peptide binding triggers conformational changes, particularly involving the movement of transmembrane helix 6, which opens the intracellular receptor interface for G-protein coupling.

Signaling Cascades and Growth Hormone Release

cAMP–PKA Pathway

The primary signaling mechanism involves coupling with Gs-type G proteins, which activate adenylyl cyclase. This enzyme catalyzes the conversion of ATP into cyclic AMP (cAMP), which subsequently activates protein kinase A (PKA).

Key PKA substrates in somatotroph cells include:

CREB

The phosphorylated form of CREB binds to promoter regions of the growth hormone gene and the GHRH receptor gene, increasing transcription.

Voltage-Dependent Calcium Channels
PKA phosphorylation increases the probability of channel opening, elevating intracellular Ca²⁺ levels and triggering exocytosis of GH-containing secretory granules.

Phosphodiesterases

PKA inhibits certain isoforms, creating a positive feedback mechanism by reducing the degradation of cAMP.

MAPK / ERK Pathway

Activation of the GHRH receptor also triggers mitogen-activated protein kinase (MAPK) cascades, which mediate proliferative responses in somatotroph cells.

The classical Ras–Raf–MEK–ERK signaling pathway becomes activated, with ERK1/2 acting as the final effector kinases.

These phosphorylated transcription factors, along with ribosomal S6 kinase and cytoskeletal proteins, play important regulatory roles.

Studies demonstrate that this pathway is particularly important for somatotroph proliferation during pituitary development and in response to increased demand for growth hormone.

Pharmacological inhibition of MEK blocks GHRH-induced proliferation without affecting cAMP generation, indicating the existence of parallel and independent signaling pathways.

Phospholipase C and Calcium Mobilization

The GHRH receptor can also couple with Gq proteins, which activate phospholipase C (PLC).

PLC cleaves PIP₂ into IP₃ and DAG.

• IP₃ triggers the release of calcium from endoplasmic reticulum stores
• DAG activates protein kinase C (PKC) isoforms

This calcium mobilization pathway complements the cAMP signaling pathway in stimulating growth hormone secretion from somatotroph cells.